Mitiglinide  (Synonyms: KAD-1229 free acid anhydrous; S21403 free acid anhydrous)

Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K⁺ (K_ATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell K_ATP channel). Mitiglinide can be used for the research of type 2 diabetes^[1][2].

K_ATP channel^[1]

Mitiglinide inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC₅₀ of 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 μM) in COS-1 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Mitiglinide (1-3 mg/kg; p.o.) suppresses the increase in plasma glucose levels seen after a meal load and the area under the curve for plasma glucose levels (AUCglucose) up to 5 h after the meal load^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

315.41

C₁₉H₂₅NO₃

145375-43-5

O=C(N1C[C@@](CCCC2)([H])[C@@]2([H])C1)C[C@@H](C(O)=O)CC3=CC=CC=C3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Y Sunaga, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001 Nov 9;431(1):119-25.  [Content Brief]

  [2]. Kiyoshi Ichikawa, et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol. May-Jun 2002;29(5-6):423-7.  [Content Brief]